# type 1 diabetes FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/type-1-diabetes

> 2 upcoming FDA catalysts in type 1 diabetes: high dose sab-142 (SABS) on November 2027 (primary completion); high dose sab-142 (SABS) on Nov 2027 to Feb 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 12, 2024 | [ZYNQUISTA® (zynquista) FDA advisory committee meeting](https://sec-api.dev/pdufa/zynquista) | LXRX | type 1 diabetes | completed, positive | "•The Advisory Committee voted 11 to 3 that the benefits of ZYNQUISTA do not outweigh the risks in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD), as defined in the voting question as having estimated glomerular filtration rate (eGFR) >45 to <60 mL/min.1.73 m2 or eGFR >60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g. .As part of the discussion, certain committee members expressed support for sotagliflozin in alternative sub-populations of people with T1D and CKD, where they believed the benefits potentially outweigh the risks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/pressreleaseearningsq311-1.htm)) |
| November 2027 | [High dose sab-142 primary completion](https://sec-api.dev/pdufa/high-dose-sab-142) | SABS | Type 1 Diabetes | scheduled | "NCT07187531 (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor SAb Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07187531)) |
| Nov 2027 to Feb 2028 | [High dose sab-142 topline data readout](https://sec-api.dev/pdufa/high-dose-sab-142) | SABS | Type 1 Diabetes | scheduled | "NCT07187531 (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor SAb Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07187531)) |

## Drugs

- [ZYNQUISTA® (zynquista)](https://sec-api.dev/pdufa/zynquista) (LXRX)
- [High dose sab-142](https://sec-api.dev/pdufa/high-dose-sab-142) (SABS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/type-1-diabetes.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "type 1 diabetes FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/type-1-diabetes

```bibtex
@misc{secapidev_indications_type_1_diabetes_20261116,
  title        = {type 1 diabetes FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/type-1-diabetes}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_type_1_diabetes_20261116","title":"type 1 diabetes FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/type-1-diabetes","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
